Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oral cancer vaccine V3-P

An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:cancer vaccine V3-P
oral tableted therapeutic vaccine V3-P
V3-P cancer vaccine
Code name:V3 P
V3-P
V3P
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search